Skip to content
Peptide research

Bronchogen

Category
Bioregulators
Administration routes
InjectableOral
Regulatory status
Not FDA-approved

What it is

Bronchogen is a short synthetic peptide marketed to repair bronchial cells and support airway gene regulation and mucus balance. Evidence is thin: benefits are low-confidence, based mainly on animal and mechanism-level work by one Russian group with no independent replication or human trials. The key gap is safety, with no established human safety profile or bioavailability data. It is not FDA-approved and sold only as an unregulated research compound.

Read Full record

Studied uses & evidence

Studied uses(8)

  • Bronchial epithelial restoration

    Low

    Reversed epithelial damage in a rat COPD model and in vitro, no human trials yet.

  • Anti-inflammatory (respiratory)

    Low

    Reduced inflammatory markers and cell infiltration in a single rat COPD study.

  • Local immune defense enhancement

    Speculative

    Increased secretory IgA in one rat study, without any infection-clearance testing.

Evidence limits

Evidence Level
Preclinical

All evidence derives from in vitro cell culture studies (human bronchial epithelial cell lines) and in vivo rat models (NO2-induced COPD). Research spans approximately 2006-2022 and originates almost entirely from Russian institutions affiliated with V.Kh. Khavinson. No independent replication by non-Russian research groups. No randomized controlled human trials. Evidence is promising but limited and lacks independent verification.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(9)

Risks = level of concern: High · Moderate · Low · Theoretical

  • No human clinical trials — safety and efficacy in humans unestablished

    High
  • Almost all research from single Russian research group (Khavinson) — no independent Western replication

    Moderate
  • Theoretical concern: gene expression modulation (NKX2-1, FOXA1/2) could affect pre-existing lung malignancies

    Theoretical
  • Potential immune enhancement via sIgA upregulation may be contraindicated in autoimmune lung conditions

    Theoretical
  • Long-term effects of chronic DNA-binding peptide administration unknown

    Theoretical
  • Oral bioavailability not rigorously characterized in peer-reviewed studies

    Moderate
  • Quality varies significantly among unregulated products sold online — no pharmaceutical-grade manufacturing standards

    Moderate
  • Pregnancy and lactation safety data absent

    Moderate
  • Interactions with bronchodilators, corticosteroids, and immunosuppressants unstudied

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.